These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 35409221)

  • 1. Identification of Novel GSK-3β Hits Using Competitive Biophysical Assays.
    Balboni B; Tripathi SK; Veronesi M; Russo D; Penna I; Giabbai B; Bandiera T; Storici P; Girotto S; Cavalli A
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The mood stabilizing properties of AF3581, a novel potent GSK-3β inhibitor.
    Capurro V; Lanfranco M; Summa M; Porceddu PF; Ciampoli M; Margaroli N; Durando L; Garrone B; Ombrato R; Tongiani S; Reggiani A
    Biomed Pharmacother; 2020 Aug; 128():110249. PubMed ID: 32470749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3β inhibitors through virtual screening.
    Zhang P; Hu HR; Huang ZH; Lei JY; Chu Y; Ye DY
    Bioorg Med Chem Lett; 2012 Dec; 22(23):7232-6. PubMed ID: 23099099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of an ESI-QTOF method for the detailed characterization of GSK-3β inhibitors.
    De Simone A; Fiori J; Naldi M; D'Urzo A; Tumiatti V; Milelli A; Andrisano V
    J Pharm Biomed Anal; 2017 Sep; 144():159-166. PubMed ID: 28268049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GSK-3β Allosteric Inhibition: A Dead End or a New Pharmacological Frontier?
    Balboni B; Masi M; Rocchia W; Girotto S; Cavalli A
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural characterization of the GSK-3beta active site using selective and non-selective ATP-mimetic inhibitors.
    Bertrand JA; Thieffine S; Vulpetti A; Cristiani C; Valsasina B; Knapp S; Kalisz HM; Flocco M
    J Mol Biol; 2003 Oct; 333(2):393-407. PubMed ID: 14529625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new protocol for predicting novel GSK-3β ATP competitive inhibitors.
    Fang J; Huang D; Zhao W; Ge H; Luo HB; Xu J
    J Chem Inf Model; 2011 Jun; 51(6):1431-8. PubMed ID: 21615159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of Selective, Substrate-Competitive, and Passive Membrane Permeable Glycogen Synthase Kinase-3β Inhibitors: Synthesis, Biological Evaluation, and Molecular Modeling of New C-Glycosylflavones.
    Liang Z; Li QX
    ACS Chem Neurosci; 2018 May; 9(5):1166-1183. PubMed ID: 29381861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Receptor-based pharmacophore modeling, virtual screening, and molecular docking studies for the discovery of novel GSK-3β inhibitors.
    El Kerdawy AM; Osman AA; Zaater MA
    J Mol Model; 2019 May; 25(6):171. PubMed ID: 31129879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereoisomers of Schisandrin B Are Potent ATP Competitive GSK-3β Inhibitors with Neuroprotective Effects against Alzheimer's Disease: Stereochemistry and Biological Activity.
    Hu XL; Guo C; Hou JQ; Feng JH; Zhang XQ; Xiong F; Ye WC; Wang H
    ACS Chem Neurosci; 2019 Feb; 10(2):996-1007. PubMed ID: 29944335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of novel quinolin-2-one derivatives as potential GSK-3β inhibitors for treatment of Alzheimer's disease: Pharmacophore-based design, preliminary SAR, in vitro and in vivo biological evaluation.
    Abdo Moustafa E; Abdelrasheed Allam H; Fouad MA; El Kerdawy AM; Nasser Eid El-Sayed N; Wagner C; Abdel-Aziz HA; Abdel Fattah Ezzat M
    Bioorg Chem; 2024 May; 146():107324. PubMed ID: 38569322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease.
    Liu W; Liu X; Tian L; Gao Y; Liu W; Chen H; Jiang X; Xu Z; Ding H; Zhao Q
    Eur J Med Chem; 2021 Oct; 222():113554. PubMed ID: 34098466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of binding affinity of 1,2-diphenyline ketone analogues at adenosine triphosphate binding site of glycogen synthase kinase-3β: a molecular docking and dynamic simulation study.
    Dinakar S; Gurubarath M; Dhananjayan K
    J Biomol Struct Dyn; 2023 Jul; 41(11):4847-4862. PubMed ID: 35543239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and in vitro evaluation of new leads as selective and competitive glycogen synthase kinase-3β inhibitors through ligand and structure based drug design.
    Darshit BS; Balaji B; Rani P; Ramanathan M
    J Mol Graph Model; 2014 Sep; 53():31-47. PubMed ID: 25064440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel hybrid virtual screening protocol based on pharmacophore and molecular docking for discovery of GSK-3β inhibitors.
    Liu X; Yu J; Luo Y; Dong H
    Chem Biol Drug Des; 2023 Feb; 101(2):326-339. PubMed ID: 35762873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular dynamics simulation studies of GSK-3β ATP competitive inhibitors: understanding the factors contributing to selectivity.
    Arfeen M; Patel R; Khan T; Bharatam PV
    J Biomol Struct Dyn; 2015; 33(12):2578-93. PubMed ID: 26209183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and bioevaluation of 1,2,4-thiadiazolidine-3,5-dione derivatives as potential GSK-3β inhibitors for the treatment of Alzheimer's disease.
    Dong Y; Lu J; Zhang S; Chen L; Wen J; Wang F; Mao Y; Li L; Zhang J; Liao S; Dong L
    Bioorg Chem; 2023 May; 134():106446. PubMed ID: 36868127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and anti-inflammatory evaluation of benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of glycogen synthase kinase-3β (GSK-3β).
    Gao Y; Zhang P; Cui A; Ye DY; Xiang M; Chu Y
    Bioorg Med Chem; 2018 Nov; 26(20):5479-5493. PubMed ID: 30293796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?
    Leclerc S; Garnier M; Hoessel R; Marko D; Bibb JA; Snyder GL; Greengard P; Biernat J; Wu YZ; Mandelkow EM; Eisenbrand G; Meijer L
    J Biol Chem; 2001 Jan; 276(1):251-60. PubMed ID: 11013232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, Bio-evaluation and Molecular Dynamics Simulation of Novel GSK-3β Inhibitors.
    Lyu W; Li Q; Li Q; Chen Y; Wang Y; Tang T; Feng F; Chi H; Li Y; Liu W; Sun H
    Mol Inform; 2021 Dec; 40(12):e2060031. PubMed ID: 34323388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.